Anticonvulsant activity of analogues of acetazolamide

Farmaco

Volumn 54, Issue 11-12, 1999, Pages 838-841

  Chufan E E ^a   Pedregosa, J C ^a   Baldini, O N ^b   Bruno Blanch, L ^b  

^a UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

^b Depto Cie Biol   (Argentina)

Author keywords

Acetazolamide; Anticonvulsant activity; Carbonic anhydrase inhibition; Maximal electroshock test; Sulfonamides

Indexed keywords

5 AMINO 1,3,4 THIADIAZOLE 2 SULFONAMIDE; 5 TERT BUTYLOXYCARBONYLAMIDO 1,3,4 THIADIAZOLE 2 SULFONAMIDE; ACETAZOLAMIDE; ANTICONVULSIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; DRUG POTENCY; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; SEIZURE;

ACETAZOLAMIDE; ANIMALS; ANTICONVULSANTS; MICE; MICE, INBRED BALB C; SULFONAMIDES; THIADIAZOLES;

EID: 0033429351     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(99)00096-8     Document Type: Article

References (18)

1. (a) C.W. Bazil, T.A. Pedley, Advances in the medical treatment of epilepsy, Annu. Rev. Med. 49 (1998) 135-162.
2. (b) D.M. Woodbury, J.W. Kemp, Other antiepileptic drugs: sulfonamides and derivatives: acetazolamide, in: R. Levy, R. Mattson, B. Meldrun, J.K. Penry, F.E. Dreifuss (Eds.), Antiepileptic Drugs, third ed., Raven Press, New York, 1989 (Chapter 61).
3. (c) S.D. Shorvon, Epidemiology, classification, natural history and genetics of epilepsy, Lancet 336 (1990) 93-96.
4. Brodi M.J. Established anticonvulsants and treatment of refractory epilepsy. Lancet. 336:1990;350-354.
5. Lindhout D., Omtzigt J.G.C. Teratogenic effects of antiepileptic drugs: implications for management of epilepsy in women of child bearing age. Epilepsia. 35:1994;S19-S28.
6. Jallon P. The problem of intractability: the continuing need for new medical therapies in epilepsy. Epilepsia. 38:1997;S37-S42.
7. Leppik I.E. Antiepileptic drugs in development: prospects for the near future. Epilepsia. 35:1994;S29-S40.
8. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E. Progress report on new antiepileptic drugs: a summary of the third Ellat conference. Epilepsica Res. 52:1997;589-593.
9. I.O. Edafigho, K.R. Scott, Anticonvulsant, in: Manfred E. Wolff (Ed.), Burger's Medicinal Chemistry and Drug Discovery, vol. 3, fifth ed., Wiley, New York, 1996, pp. 175-260 (Chapter 39).
10. Ragsdale D.S., Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res. Rev. 26:1998;16-28.
11. 2 dimer complex. Inorg. Chim. Acta. 232:1995;117-224.
12. Supuran C., Balaban A.T., Gheorghiu M.D., Schiketanz A., Dinculescu A., Puscas I. Carbonic anhydrase inhibitors. Part 2. Membrane-impermeable derivatives of 1,3,4-thiadiazole-2-sulfonamide. Rev. Roum. Chim. 35:1990;399-403.
13. Maren T.H. Carbonic anhydrase: chemistry, physiology and inhibition. Physiol. Rev. 47:1967;595-604.
14. Maren T.H. A simplified method for the determination of carbonic anhydrase and its inhibitors. J. Pharmacol. Exp. Ther. 130:1960;25-32.
15. Gladding G.D., Kupferberg H.J., Swinyard E.A. Antiepileptic drugs. Frey H., Janz D. Handbook of Experimental Pharmacology 74. 342:1985;Springer, Berlin.
16. White H.S., Woodhead J.H., Franklin M.R., Swinyard E.A., Wolf H.H. Experimental selection, quantification and evaluation of anticonvulsants. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. fourth ed. 1995;99-109 Raven Press, New York.
17. Supuran C.T. Puscas I. Carbonic Anhydrase and Modulation of Physiologic and 1222 Pathologic Processes in the Organism. 1994;29-113 Helicon, Timisoara, Romania.
18. I.O. Edafiogho, K.R. Scott, Anticonvulsants, in: M.E. Wolff (Ed.), Burger's Medicinal Chemistry and Drug Discovery, vol. 3, 1996, pp. 175-260 (Chapter 39).